Author: Mary-Louise Hoffman|| Date Published: August 1, 2023
Emergent BioSolutions (NYSE: EBS) will further develop a licensed drug against Ebola under a potential 10-year, $704 million contract from the Department of Health and Human Services.
Development services on Ebanga under the contract are valued at $121 million and the award includes a five-year option worth $583 million for the U.S. government to procure the monoclonal antibody product, Emergent said Monday.
The biopharmaceutical company will use the federal funds to scale up its manufacturing process, apply for a supplemental biologics license with the Food and Drug Administration and complete stability research.
Ebanga, developed by Ridgeback Biotherapeutics through a National Institute of Allergy and Infectious Diseases license, is given via a single infusion to exhibit antiviral activity.
HHS’ Biomedical Advanced Research and Development Authority previously awarded funds for the developer to put its anti-Ebola product through late-stage production and regulatory activities.
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
Precision Aerospace & Defense Group and FACT II Acquisition, a special purpose acquisition company, have signed a definitive business combination agreement to…
LMI has announced the acquisition of intellectual property and advanced capabilities to broaden its in-transit visibility and asset tracking services for…
